Ketamine and Augmentation Therapy: Drug Interactions and Monitoring
When administering acute ketamine to adults on augmentation therapy (aripiprazole, lithium, or sertraline), the primary concern is that benzodiazepines—not the augmentation agents themselves—may reduce ketamine's antidepressant efficacy, while the augmentation medications show minimal clinically significant pharmacodynamic interactions.
Key Pharmacodynamic Interactions
Aripiprazole
Aripiprazole demonstrates minimal interaction with ketamine in the available evidence. The 2018 ESMO guidelines note that aripiprazole requires caution for cytochrome P450 2D6 and 3A4 drug-drug interactions 1, but ketamine is primarily metabolized by CYP2B6 and CYP3A4 2. A systematic review found no significant pharmacodynamic interactions between ketamine and aripiprazole that would alter treatment outcomes 3. The 2025 INTEGRATE guidelines support aripiprazole augmentation in psychiatric treatment without specific contraindications for concurrent ketamine use 4.
Lithium
No significant interactions between lithium and ketamine have been reported 3. The 2002 Alzheimer's guidelines indicate lithium is used for anticycling and antidepressant augmentation at blood levels of 0.2-0.6 mEq/L 5, and this therapeutic range does not appear to interfere with ketamine's mechanism of action as an NMDA receptor antagonist 2.
Sertraline
Sertraline, an SSRI, has no documented pharmacodynamic interactions with ketamine that would alter safety or efficacy. The 2002 guidelines note sertraline is well-tolerated with less effect on metabolism of other medications compared to other SSRIs 5. While theoretical concerns about serotonin syndrome exist when combining any serotonergic agents, ketamine's primary mechanism is NMDA antagonism 2, making clinically significant serotonin syndrome unlikely at standard ketamine doses.
Critical Interaction: Benzodiazepines
The most clinically significant interaction is with benzodiazepines, which repeatedly reduce the duration of ketamine's antidepressant effect 3. This is particularly relevant because:
- Benzodiazepines are commonly co-prescribed in psychiatric populations
- The 2018 ESMO guidelines warn of oversedation risk when combining benzodiazepines with antipsychotics 1
- If the patient is on benzodiazepines for anxiety or agitation, consider tapering or holding doses around ketamine administration
Cardiovascular Monitoring
Ketamine increases blood pressure, heart rate, and cardiac output through sympathomimetic activity 2. The FDA label specifies that systolic and diastolic blood pressure typically peak 10-50% above baseline within minutes of injection, returning to baseline within 15 minutes 2.
Monitor continuously:
- Blood pressure and heart rate during infusion and for 15-30 minutes post-administration
- ECG monitoring if administering IV (per FDA label) 1
- Oxygen saturation, as transient respiratory depression can occur 6
The 2023 cardiac arrest sedation guidelines recommend lower ketamine doses in patients with shock, as it can suppress myocardial contractility when catecholamine reserves are depleted 7.
Dosing Considerations
For acute ketamine administration in adults:
- Standard IV dose: 0.5 mg/kg infused over 40 minutes for antidepressant/analgesic effects 8, 9, 10
- IM dose: 0.75-2.0 mg/kg when IV access unavailable 11, 12
- The 2022 VA/DoD guidelines support ketamine for treatment-resistant depression after failure of at least 2 adequate antidepressant trials 8
Emergence Reactions
Ketamine-induced emergence delirium (floating sensations, hallucinations, agitation) occurs in 10-30% of adults 11, 12, 2. The FDA label and multiple guidelines note that co-administration of benzodiazepines minimizes emergence reactions 11, 12, 2. However, this creates a clinical dilemma: benzodiazepines reduce emergence phenomena but may diminish antidepressant efficacy 3.
Practical approach:
- Avoid scheduled benzodiazepines before/during ketamine if treating depression
- Have benzodiazepines available for rescue if severe emergence reactions occur
- Consider lower ketamine doses (0.3-0.4 mg/kg) to reduce emergence risk
Metabolic Considerations
Ketamine is metabolized to norketamine (active metabolite) primarily via CYP2B6 and CYP3A4 2. Norketamine has approximately 1/3 the potency of ketamine 2. Neither aripiprazole, lithium, nor sertraline significantly inhibit or induce these pathways at therapeutic doses, making pharmacokinetic interactions unlikely.
Common Pitfalls to Avoid
Do not assume all psychiatric medications interact similarly—the evidence shows benzodiazepines and possibly lamotrigine reduce ketamine efficacy, but mood stabilizers like lithium and antipsychotics like aripiprazole do not 3
Do not withhold cardiovascular monitoring—even in healthy adults, ketamine's sympathomimetic effects require blood pressure and heart rate monitoring 2
Do not use ketamine as first-line treatment—the 2022 VA/DoD guidelines reserve ketamine for patients who have failed multiple antidepressant trials 8
Do not overlook QTc prolongation risk—while aripiprazole has lower risk than haloperidol, the 2018 ESMO guidelines note QTc monitoring is prudent when combining multiple psychiatric medications 1